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The molecular mechanisms underlying the pathophysiology of Alzheimer’s disease (AD)
are still not fully understood. In AD, Wnt/beta-catenin signaling has been shown to
be downregulated while the peroxisome proliferator-activated receptor (PPAR) gamma
(mARN and protein) is upregulated. Certain neurodegenerative diseases share the same
Wnt/beta-catenin/PPAR gamma profile, such as bipolar disorder and schizophrenia.
Conversely, other NDs share an opposite profile, such as amyotrophic lateral sclerosis,
Parkinson’s disease, Huntington’s disease, multiple sclerosis, and Friedreich’s ataxia. AD
is characterized by the deposition of extracellular Abeta plaques and the formation of
intracellular neurofibrillary tangles in the central nervous system (CNS). Activation of Wnt
signaling or inhibition of both glycogen synthase kinase-3beta and Dickkopf 1, two key
negative regulators of the canonical Wnt pathway, are able to protect against Abeta
neurotoxicity and to ameliorate cognitive performance in AD patients. Although PPAR
gamma is upregulated in AD patients, and despite the fact that it has been shown
that the PPAR gamma and Wnt/beta catenin pathway systems work in an opposite
manner, PPAR gamma agonists diminish learning and memory deficits, decrease Abeta
activation of microglia, and prevent hippocampal and cortical neurons from dying. These
beneficial effects observed in AD transgenic mice and patients might be partially due
to the anti-inflammatory properties of PPAR gamma agonists. Moreover, activation of
PPAR alpha upregulates transcription of the alpha-secretase gene and represents a new
therapeutic treatment for AD. This review focuses largely on the behavior of two opposing
pathways in AD, namely Wnt/beta-catenin signaling and PPAR gamma. It is hoped that
this approach may help to develop novel AD therapeutic strategies integrating PPAR
alpha signaling.
Keywords: PPAR alpha, PPAR gamma, Wnt/beta-catenin, Alzheimer disease, lithium, riluzole, glycogen synthase
kinase-3beta
INTRODUCTION
Alzheimer disease (AD) represents the most common form of neurodegenerative dementia.
The AD pathophysiology is not completely understood but is characterized by the deposition
of extracellular Abeta plaques (Abeta) and the formation of intracellular neurofibrillary tangles
(NFTs) in the central nervous system (CNS) (Mattson, 2004; Mayeux and Stern, 2012). Certain
Vallée and Lecarpentier Alzheimer Disease, Wnt and PPARs
neurodegenerative diseases (NDs) have recently been classified
into two categories (Lecarpentier et al., 2014). Amyotrophic
lateral sclerosis (Lecarpentier and Vallee, 2016), Parkinson’s
disease, Huntington’s disease, multiple sclerosis and Friedreich’s
ataxia represent NDs in which the canonical Wnt/beta-catenin
pathway is upregulated while PPAR gamma is downregulated.
Conversely, AD, bipolar disorder and schizophrenia are NDs in
which the canonicalWnt/beta-catenin pathway is downregulated
while PPAR gamma is upregulated. Thus, stimulating Wnt/beta-
catenin signaling could represent a promising therapeutic target
for human AD treatment, since its activation protects neurons
against Abeta toxicity, the hallmark of the disease (Mao et al.,
2001; Alvarez et al., 2004; Boonen et al., 2009; Fiorentini et al.,
2010; Shruster et al., 2011; Zhang et al., 2011; Inestrosa et al.,
2012, 2015). Importantly, PPAR gamma levels (mRNA and
protein) have been found to be elevated in AD brain tissues
(Kitamura et al., 1999; de la Monte and Wands, 2006). Although
PPAR gamma expression is high in AD, PPAR gamma agonists
have been used in AD for both humans and animal models and
have been shown to induce beneficial effects (Combs et al., 2000;
Sastre et al., 2003; Camacho et al., 2004; D’Abramo et al., 2005;
Pedersen et al., 2006; Risner et al., 2006; Escribano et al., 2010).
Given that in numerous tissues and pathological states PPAR
gamma activation induces repression of the Wnt/beta-catenin
pathway (Moldes et al., 2003; Sharma et al., 2004; Liu et al.,
2006), the rationale for using PPAR gamma in AD would seem
to merit discussion. The anti-inflammatory properties induced
by PPAR gamma agonists may partly explain their beneficial
therapeutic effects. Compared with PPAR gamma, PPAR alpha
has been poorly studied in AD. PPAR alpha levels (mRNA and
protein) have been found to be low in AD brain tissues (de
la Monte and Wands, 2006) and a recent study highlights the
interest of studying PPAR alpha signaling in AD (Corbett et al.,
2015). In numerous diseases, PPAR gamma expression varies in
an opposite way to that of both PPAR alpha and Wnt signaling.
The links between Wnt/beta-catenin signaling and PPARs alpha
and gamma in AD are reviewed here.
THE CANONICAL WNT/BETA-CATENIN
PATHWAY
The Wnt/beta-catenin pathway (Figure 1) plays an important
role in embryonic development and cell fate and its dysregulation
is implicated in numerous pathological processes such as
carcinogenesis (Moon et al., 2002, 2004; Nusse, 2005; Clevers,
2006). In the absence of Wnt activation (“off state”), cytosolic
beta-catenin is phosphorylated by GSK-3beta. APC and Axin
combine with GSK-3beta and beta-catenin in the destruction
Abbreviations: APC, adenomatous polyposis coli; AD, Alzheimer’s disease;
APP, amyloid precursor proteins; ARVC, arrhythmogenic right ventricular
dysplasia/cardiomyopathy; CNS, central nervous system; DKK1, Dickkopf 1; Dsh,
Disheveled; Fzd, Frizzled; GSK-3beta, glycogen synthase kinase-3beta; LRP5/6low,
density lipoprotein receptor-related protein 5/6; MAP, microtubule-associated
protein; NDs, neurodegenerative diseases; NFTs, neurofibrillary tangle; NSAIDs,
non-steroidal anti-inflammatory drugs; PPAR, peroxisome proliferator-activated
receptor; TZDs, thiazolidinediones.
FIGURE 1 | A schematic model of the Wnt/beta-catenin pathway. In the
Wnt “on state” (right part), Wnt binds both Fzd and LRP5/6 receptors to
initiate LRP phosphorylation as well as Dsh/Fzd internalization. Dsh membrane
translocation leads to dissociation of the axin/APC/GSK-3β complex.
Beta-catenin phosphorylation is inhibited and it accumulates in the cytosol.
The cytosolic beta-catenin translocates to the nucleus and binds to TCF/LEF
factors. This results in the Wnt-responsive gene transcription. In Wnt “off state”
(left part), Dsh dissociates from Fzd and Axin. APC and axin complex with
GSK-3β. Beta-catenin is phosphorylated, dissociates from GSK-3β, migrates
to the cytosol and is destroyed in the proteasome. Abbreviations: APC,
adenomatous polyposis coli; Dsh, Disheveled; Fzd, Frizzled; GSK-3β,
glycogen synthase kinase-3beta; LRP5/6, low density lipoprotein
receptor-related protein 5/6; TCF/LEF, T-cell factor /lymphoid enhancer factor.
complex. This leads to destruction of the phosphorylated beta-
catenin, which is degraded in the proteasome. In the presence
of Wnt activation (“on state”), Wnt ligands bind both Fzd
and LRP5/6 receptors. Dsh binds to axin, which prevents the
GSK-3beta phosphorylation of beta-catenin. Then, beta-catenin
accumulates in the cytosol, translocates to the nucleus and
ultimately binds to LEF/TCF co-transcription factors. This leads
to the transcription of Wnt-responsive genes including PPAR
beta/delta, Axin-2, cyclin D1, CD44, c-myc, and Cox2 (He et al.,




PPARs alpha, beta/delta, and gamma are ligand-activated
transcriptional factor that belong to the nuclear hormone
receptor superfamily. They heterodimerize with the retinoid X
receptor and bind to peroxisome proliferator response elements
which are specific regions on the DNA of target genes. PPAR
alpha has been first discovered and characterized as a rodent
hepatocarcinogen that causes proliferation of peroxisomes.
PPAR alpha is a key regulator of lipid metabolism and is
activated under conditions of energy deprivation. It is highly
expressed in tissues that oxidize fatty acids at a rapid rate
and activates numerous genes involved in cellular fatty acid
uptake, mitochondrial fatty acid beta-oxidation and lipoprotein
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metabolism (Desvergne and Wahli, 1999; Watanabe et al., 2000).
PPAR alpha is activated by endogenous ligands or by synthetic
ligands such as fibrates which are used in the treatment of
hyperlipidemia.
PPAR gamma is expressed in various cellular types, including
adipose tissues, immune cells, and brain cells (astrocytes and
microglia). It regulates glucose homeostasis, insulin sensitivity,
lipid metabolism, cell fate, immune responses, inflammation,
and cardiovascular function (Elbrecht et al., 1996; Fajas et al.,
1997; Desvergne andWahli, 1999). PPAR gamma is dysregulated
in various diseases including obesity, type 2 diabetes, cancers
and atherosclerosis. PPAR gamma agonists thiazolidinediones
(TZDs) are insulin sensitizing molecules and some of them
are used in the type 2 diabetes treatment (Picard and Auwerx,
2002; Rangwala and Lazar, 2004). TZDs act on the promoters of
GLUT2 and beta- glucokinase in pancreatic beta-cells and liver.
PPAR gamma controls circadian variations in blood pressure
and heart rate through the clock gene BMAL1 (Wang et al.,
2008) and plays a role in the occurrence of instabilities in
systems that thermodynamically behave far-from-equilibrium
(Prigogine and Nicolis, 1971; Lecarpentier et al., 2010). PPAR
gamma induces neuroprotective and anti-inflammatory effects
(Kapadia et al., 2008; Gray et al., 2012; Katsouri et al.,
2012). PPAR gamma ligands induce beneficial effects in many
NDs such as amyotrophic lateral sclerosis, Parkinson’s disease,





PPAR Gamma Agonists Induce
Beta-Catenin Inhibition
PPAR gamma and the Wnt/beta-catenin pathway have been
shown to behave in an opposite manner (Gerhold et al., 2002;
Girnun et al., 2002a,b; Sharma et al., 2004; Takada et al., 2009;
Lu and Carson, 2010). The functional interplay between PPAR
gamma and Wnt/beta-catenin signaling implicates the TCF/LEF
binding domain of beta-catenin and a catenin binding domain
(CBD) within PPAR gamma. (Liu et al., 2006). Heterozygous
loss of PPAR gamma increases the beta-catenin level in a
genetic model of colon cancer. Thus, PPAR gamma can inhibit
beta-catenin (Girnun et al., 2002b). Conversely, beta-catenin
can directly interact with PPAR gamma and RXR alpha (Xiao
et al., 2003; Jansson et al., 2005; Liu et al., 2006). TZDs PPAR
gamma agonists repress beta-catenin-dependent transcription
(Lu and Carson, 2010). Activation of PPAR gamma induces the
proteasomal degradation of beta-catenin in cells that express an
APC-containing destruction complex, although oncogenic beta-
catenin inhibits the expression of PPAR gamma target genes
(Liu et al., 2006). PPAR gamma inhibits osteoblastogenesis,
promotes adipogenesis and suppresses the Wnt/beta-catenin
pathway during adipogenesis (Moldes et al., 2003; Takada et al.,
2009). TZDs induce a reduction in the levels of cytoplasmic
beta-catenin in 3T3L1 adipocytes (Gerhold et al., 2002) and
in hepatocytes (Sharma et al., 2004). Conversely Wnt/beta-
catenin signaling activation inhibits PPAR gamma and leads to
osteogenesis (Takada et al., 2009).
Inhibition of Wnt/Beta-Catenin Pathway
Induces Activation of PPAR Gamma
Deactivation of the Wnt/beta catenin pathway and activation
of PPAR gamma are observed in arrhythmogenic right
ventricular cardiomyopathy (ARVC) (Garcia-Gras et al., 2006;
Djouadi et al., 2009). Gamma-catenin (or plakoglobin), which
presents structural similarities with beta-catenin (Moon et al.,
2002), translocates to the nucleus, competes with beta-catenin
and inhibits Wnt/beta-catenin signaling through TCF/LEF
transcription factors (Zhurinsky et al., 2000). This enhances
adipogenesis, thus summarizing the phenotype of the human
ARVC (Garcia-Gras et al., 2006; Djouadi et al., 2009).
ALZHEIMER’S DISEASE (AD)
GENERALITIES
The molecular mechanisms underlying the pathophysiology
of AD are still not fully understood. AD is characterized by
the deposition of extracellular Abeta plaques (Abeta) and the
formation of NFTs in the CNS. NFTs contain the aggregated
hyperphosphorylated microtubule-associated protein (MAP)
tau. Abeta plaques induce neural dysfunction and cognitive
impairment (Mattson, 2004; Buée et al., 2010; Mayeux and
Stern, 2012). There is an extracellular beta-amyloid deposition in
specific regions of the brain which contains Abeta peptides. These
protein fragments derive from proteolytic cleavage of the amyloid
precursor protein (APP), a membrane protein (Hicks et al., 2013;
Nalivaeva and Turner, 2013; Figure 2).
The hypothesis of AD amyloid cascade has been formulated
by Hardy and Higgins (Hardy and Higgins, 1992). In AD
there is an accumulation of extracellular amyloid aggregates of
amyloid β peptide (Abeta) (or senile plaques) and intracellular
neurofibrillary tangles of hyperphosphorylated tau protein. Abeta
oligomers are toxic and accumulate particularly in the neocortex
and hippocampus (Sisodia and Gallagher, 1998). APP is a type
1 integral membrane protein with three isoforms (Sandbrink
et al., 1996). There are two proteolytic pathways for APP
processes. The first one pathway, the amyloidogenic, involves
the sequential cleavage of APP by β- and γ-secretases, leading
to the release of a soluble ectodomain sAPPβ and Aβ peptide
(Zhang et al., 2012). The second pathway, the non-amyloidogenic
pathway, involves the α-secretase cleavage of APP (Allinson
et al., 2003) and precludes Abeta formation. Abeta forms
dimers and higher level oligomers which cause neuronal death.
Abeta aggregates with other proteins to form amyloid plaques.
Solube sAPPα ectodomain has neuroprotective properties
(Figure 2).
Under physiological conditions, Abeta is released into the
interstitial fluid of the brain. This improves the synapse function
and neuronal activity (Palop and Mucke, 2010). In AD, Abeta
contributes to AD development (Mattson, 2004; Wan et al.,
2014a). Abeta is associated with progression of the disease. Its
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FIGURE 2 | A schematic model of the Wnt/beta-catenin pathway in
Alzheimer disease. In AD, the “on state” of canonical Wnt/beta-catenin
pathway is interrupted at two potential levels. Firstly, extracellular Aβ activates
DKK1 which inhibits the interaction between Wnt and LRP 5/6. Binding of Wnt
to Fzd is suppressed and Dsh dissociates from Fzd/Axin and migrates to the
cytosol. The recruitment of the destruction complex to the plasma membrane
is suppressed. Inactivation of Dsh leads to stimulation of GSK-3β. Thus, APC
and AXIN interact with GSK-3β and beta-catenin (Wnt “off state”). Beta-catenin
is phosphorylated by GSK-3β. The destruction complex AXIN/APC/GSK-3β is
activated and enhances the destruction process of beta-catenin in the
proteasome. Secondly, PPAR gamma which is activated by agonists can
inhibit the beta-catenin/TCF/LEF complex in the nucleus, thus inhibiting the
transcription of Wnt target genes. Amyloid precursor protein (APP) can be cut
into various fragments by α, β, and γ secretases. PPAR α activates the
transcription of α secretase. Abbreviations APC, adenomatous polyposis coli;
Dsh, Disheveled; Fzd, Frizzled; GSK-3β, glycogen synthase kinase-3beta;
LRP5/6, low density lipoprotein receptor-related protein 5/6; TCF/LEF, T-cell
factor /lymphoid enhancer factor; sAPPα, soluble APPα ectodomain; sAPPβ,
soluble APPβ ectodomain; APP, Amyloid precursor protein; α, β, and γ, α, β,
and γ secretases; Aβ, amyloid β peptide; DKK1, Dickkopf-related protein1.
accumulation is thought to be responsible for neuroinflammation
and to contribute to the AD pathophysiology. This results in CNS
damages associated with impairment of hippocampal synaptic
plasticity, progressive loss of the cognitive function and long-
term depression (Mattson, 2004; Shankar et al., 2008; Cerpa et al.,
2010; Palop and Mucke, 2010).
The Canonical Wnt/Beta-Catenin Pathway
in AD
Wnt pathways have been shown to be involved in several
neuronal processes during embryonic development: synaptic
differentiation, the function of neuronal circuits (by controlling
neuronal differentiation), dendrite development, synaptic
function, and neuronal plasticity (Rosso and Inestrosa, 2013).
Wnt proteins participate in the remodeling of pre- and post-
synaptic regions. Wnt proteins are constantly released in the
brain to maintain the basal neural activity (Oliva et al., 2013b).
Wnt is involved in adult neurogenesis and protects excitatory
synaptic terminals from Abeta toxicity. There is a relationship
between the loss of Wnt signaling and the neurotoxicity of Abeta
in AD (Inestrosa et al., 2012). An endogenous Wnt-3a ligand
prevents the toxic effects induced by Abeta in rat hippocampal
neurons and protects hippocampal neurons from apoptosis
induced by Abeta. The Wnt pathway is able to overcome
the increase in GSK-3beta and tau phosphorylation and the
decrease in cytoplasmic beta-catenin (Alvarez et al., 2004).
Overexpression of Fzd-1 increases the Wnt-3a-induced cell
survival, while inhibition of Fzd-1 reverses the Wnt-3a-induced
beneficial effects. In PC12 cells, Wnt-3a increases beta-catenin
expression (Kawamoto et al., 2012). Numerous other studies
have observed a downregulation of Wnt/beta-catenin signaling
in the pathogenesis of AD. This is attested by either a decreased
level of beta-catenin or increased activity of both GSK-3beta and
Dickkopf-1 (DKK1), two inhibitors of Wnt signaling (Rosi et al.,
2010; Clevers and Nusse, 2012; Inestrosa et al., 2012).
Abeta Represses the Canonical Wnt
Pathway, While Activation of Wnt Signaling
Attenuates Abeta Neurotoxicity
Dysfunction of the Wnt pathway induced by Abeta has been
reported in AD (Thies, 2011; Silva-Alvarez et al., 2013; Wan
et al., 2014b). Hyperphosphorylated tau and Abeta induce
neuronal death and are responsible for a decrease in the
cognitive function and progressive loss of memory (Price
et al., 1998). Active Abeta plaques are found in abundance
in microglia and astrocytes (Akiyama et al., 2000). In AD,
Abeta downregulates the Wnt pathway. This is accompanied
by synapse alteration and neuron degeneration (Silva-Alvarez
et al., 2013). Cellular damages induced by Abeta are reversed by
inhibition of GSK-3beta (Li et al., 2013). In AD, Wnt signaling
activation induces neuroprotective effects via Wnt-3a (Alvarez
et al., 2004), Wnt-5a, and Wnt-7a (Quintanilla et al., 2005),
attenuates deleterious effects induced by Abeta, and facilitates the
behavior of hippocampal neurons (Alvarez et al., 2004; Cerpa
et al., 2010; Silva-Alvarez et al., 2013). In rat hyppocampal
neurons, activation of the Wnt pathway by Wnt-3a prevents the
Abeta-induced toxic effects, induces a decrease in GSK-3beta
and tau phosphorylation and increases the level of cytoplasmic
beta-catenin (Alvarez et al., 2004).
GSK-3beta, a Negative Regulator of the
Canonical Wnt Pathway
GSK-3beta inhibition induces neuroprotection in a transgenic
AD model and in hippocampal cultured neurons. In the
hippocampus of AD patients, increased GSK-3beta helps
decrease the beta-catenin level and increase tau phosphorylation
and NFTs formation (Oliva et al., 2013a). GSK-3beta
phosphorylates MAP tau leading to NFTs (Buée et al.,
2010; Mendoza et al., 2013; Rosso and Inestrosa, 2013). In
the hippocampus of AD patients, both the expression and
activity of GSK-3beta are augmented (Hooper et al., 2008;
Oliva et al., 2013b). In AD, increased GSK-3beta expression
is linked to memory abnormalities (Hooper et al., 2007;
Killick et al., 2014). Moreover, activation of GSK-3beta
stimulates the APP cleavage (Phiel et al., 2003; Inestrosa
and Varela-Nallar, 2014). Activation of Wnt signaling via
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GSK-3beta inhibition favors neuroprotection (Vargas et al.,
2014).
DKK-1, a Negative Regulator of the
Canonical Wnt Pathway
DKK-1, a secreted glycoprotein, is favored by Abeta. Its
expression is increased in AD. DKK-1 binds with LRP 5/6,
blocks Wnt /Frd interaction and inhibits interaction with Wnt
ligands (Mao et al., 2001; Figure 2). DKK-1 and Wnt ligands
have two distinct sites on LRP 5/6. DKK-1 colocalizes with
both hyperphosphorylated tau andGSK-3beta staining. Exposure
of cultures to Abeta induces the expression of DKK1. DKK1
negatively modulates the Wnt pathway and activates the tau-
phosphorylating GSK-3beta. An increase in DKK-1 is observed
in the AD brain of humans and transgenic mice (Caricasole et al.,
2004; Palop and Mucke, 2010; Rosi et al., 2010). DKK-1 silencing
favors the phosphorylated form of GSK-3beta (Caricasole et al.,
2004). DKK-1 is involved in synapse loss due to Abeta. DKK-
1 antibodies suppress the synaptic loss due to Abeta in mouse
brain (Purro et al., 2012). Inhibition of DKK-1 protects against
Abeta-induced apoptosis. The secreted Wnt antagonist DKK-1
is required for amyloid beta-mediated synaptic loss (Caricasole
et al., 2004; Rosi et al., 2010; Purro et al., 2012; Killick et al., 2014).
The plasma cholesterol transport molecule, Apo-E4, induces
inhibition of Wnt signaling in PC12 cells and indirectly increases
DKK-1 expression, thereby enhancing Abeta toxicity (Caruso
et al., 2006; De Ferrari et al., 2007; Donahue and Johanson,
2008).
Thus, activation of the Wnt pathway via Wnt ligands or
inhibition of key negative regulators of the Wnt pathway, such
as DKK-1 and GSK-3beta, are able to protect against Abeta
neurotoxicity and to ameliorate cognitive performance in AD
patients (Alvarez et al., 2004; Rosi et al., 2010; Shruster et al.,
2011; Clevers and Nusse, 2012; Maguschak and Ressler, 2012a,b;
Purro et al., 2012; Vargas et al., 2014). DKK1 contributes to the
pathological cascade triggered by Abeta and is critically involved
in tau phosphorylation.
Lithium, an Inhibitor of GSK-3beta
The GSK-3beta inhibitor, lithium chloride, regulates adult
hippocampal progenitor development through Wnt pathway
activation (Wexler et al., 2008). Lithium chloride enhances
activation of Wnt signaling (Hedgepeth et al., 1997; Sinha
et al., 2005; Galli et al., 2013). Rat neurons are protected from
Abeta by lithium (Inestrosa et al., 2012). Lithium activates
the Wnt signaling in cultured hippocampal neurons and
induces a neuronal protection in AD transgenic mice. Abeta
exacerbates the neuronal dysfunction caused by tau expression
in a Drosophila model of AD and treatment of flies with lithium
attenuates the effects of Abeta (Folwell et al., 2010). Lithium
improves hippocampal cognitive functions and neurogenesis in
APP mice (Fiorentini et al., 2010). Lithium or Wnt ligands in
AD animal models or in primary hippocampal neurons attenuate
Abeta toxicity by recovering beta-catenin levels (Fuentealba et al.,
2004).
Riluzole, an Enhancer of Canonical
Wnt/Beta-Catenin Signaling
Riluzole rescues glutamate alterations, cognitive deficits, and tau
pathology associated with P301L tau expression (Hunsberger
et al., 2015; Whitcomb and Molnar, 2015). Riluzole improves
performance in the rTg (TauP301L) 4510 mouse model of
AD. The TauP301L-mediated reduction in PSD-95 expression, a
marker of excitatory synapses in the hippocampus, is rescued by
riluzole. However, it has been shown that riluzole is an enhancer
of Wnt/beta-catenin signaling in both HT22 neuronal cells and
adult hippocampal progenitor cells (Biechele et al., 2010). This
may partly explain the beneficial results induced by riluzole
in AD mice. Conversely, riluzole has been approved for the
treatment of amyotrophic sclerosis (ALS), a disease in which the
Wnt/beta-catenin signaling is upregulated. It has been used in
ALS due to its role in glutamate toxicity. Thus, riluzole induces
various effects on the presynaptic inhibition of the glutamate
release and the blockade of the voltage-gated sodium channel
(Aggarwal and Cudkowicz, 2008). However, in ALS, riluzole
presents a weak efficacy with prolongation of median survival
by about 3 months (Bensimon et al., 1994; Lacomblez et al.,
1996; Miller et al., 2003, 2012). This may partly explain the poor
results obtained by using riluzole in ALS where the Wnt/beta
catenin signaling is upregulated (Lecarpentier and Vallee, 2016).
Wnt/beta-catenin signaling is downregulated in bipolar disorder
and riluzole reduces symptoms in this disease (Gould and
Manji, 2002; Pittenger et al., 2008; Valvezan and Klein, 2012).
Similarly, by stimulating Wnt/beta-catenin signaling, riluzole
could be an interesting target for AD treatment (Biechele et al.,
2010).
Other Activators of the Wnt/Beta-Catenin
Pathway in AD: Curcumin, Huperzine A, M1
Muscarinic Receptors
Curcumin activates the Wnt/beta-catenin pathway through
inhibition of GSK-3beta activity in APPswe transfected SY5Y
cells and increases the translocation of beta-catenin to the
nucleus (Zhang et al., 2011). In transfected cells treated with
Curcumin, expression of GSK-3beta diminishes in a dose-
and time-dependent manner. In AD brains, Huperzine A,
an acetylcholine inhibitor, inhibits GSK-3beta, activates Wnt
signaling and stabilizes the cytosolic beta-catenin level (Wang
et al., 2011). M1 muscarinic receptor activation protects neurons
from beta-amyloid toxicity (Farías et al., 2004; Caccamo et al.,
2006).
Cannabidiol, a non-psychoactive marijuana component, has
been shown to rescue PC12 cells from toxicity induced by
Abeta peptide (Esposito et al., 2006). Cannabidiol inhibits
hyperphosphorylation of tau protein in Abeta-stimulated PC12
neuronal cells and its effect is mediated through the Wnt/beta-
catenin pathway. Taken together, all these data suggest a positive
feedback loop between the canonical Wnt pathway and Abeta.
Thus, activation of Wnt signaling could represent a promising
target for the treatment of AD (Mao et al., 2001; Alvarez et al.,
2004; Farías et al., 2004; Caccamo et al., 2006; Wexler et al., 2008;
Boonen et al., 2009; Cerpa et al., 2010; Fiorentini et al., 2010;
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Shruster et al., 2011; Zhang et al., 2011; Inestrosa et al., 2012;
Kawamoto et al., 2012; De Ferrari et al., 2014).
Canonical Wnt/Beta-Catenin Pathway and
PPAR Gamma Behave in an Opposite
Manner in AD
In the adult brain and under physiological conditions, the
expression of PPAR gamma has been reported to be at a low
level (Kummer and Heneka, 2008). Conversely in AD brains,
both PPAR gamma protein levels (Kitamura et al., 1999) and
PPAR gamma mRNA levels (de la Monte and Wands, 2006)
have been shown to be elevated. Moreover, the Wnt pathway
is downregulated in AD (Thies, 2011; Silva-Alvarez et al., 2013;
Wan et al., 2014b). As indicated earlier, several studies have
shown that PPAR gamma and the Wnt/beta-catenin pathway
operate through an antagonistic manner (Gerhold et al., 2002;
Moldes et al., 2003; Sharma et al., 2004; Garcia-Gras et al., 2006;
Liu et al., 2006; Takada et al., 2009; Lu and Carson, 2010). Other
diseases present a similar profile in terms of Wnt/beta-catenin
/PPAR gamma signaling, i.e., ARVC, osteoporosis, cardiac
hypertrophy, bipolar disorder, and schizophrenia (Lecarpentier
et al., 2014). Thus, the high PPAR gamma levels observed in
AD may contribute to inhibit the Wnt/beta-catenin pathway
(Figure 2). Consequently, the rationale that leads to the use
of PPAR gamma agonists to treat AD would seem to merit
discussion.
Inflammation in AD
PPAR gamma is able to induce anti-inflammatory effects and this
leads to the hypothesis that PPAR gamma might be beneficial
in CNS diseases presenting inflammatory processes, especially
AD. The anti-inflammatory effects of PPAR gamma may be
explained by the fact that PPAR gamma is able to inhibit several
pathways by interacting directly on NFκB, AP-1, STAT1, and
NFAT (Daynes and Jones, 2002; Pascual et al., 2005). Moreover,
troglitazone can induce anti-inflammatory effects on neurons
independently of its PPAR gamma activity (Nishijima et al.,
2001). Pioglitazone has a low penetration through the blood
brain barrier (Maeshiba et al., 1997), while rosiglitazone does not
penetrate the blood brain barrier at all (Chalimoniuk et al., 2004;
Risner et al., 2006). However, rosiglitazone improves cognition in
AD patients (Risner et al., 2006). In AD, inflammatory processes
in microglia and the presence of inflammatory molecules may
generate neuronal loss, contributing to the progression of the
disease (Tanzi and Bertram, 2005; Heneka and O’Banion, 2007).
Interleukins, TNF, monocyte chemotactic protein-1 are present
in microglia (Sly et al., 2001). INos is expressed in AD brain and
contributes to inflammation (Vodovotz et al., 1996; Lee et al.,
1999; Heneka et al., 2001b). Although PPAR gamma protein and
mRNA levels are high, the anti-inflammatory effects of PPAR
gamma agonists could nevertheless justify their use in AD.
Dual Effects of NSAIDs in AD
Non-steroidal anti-inflammatory drugs (NSAIDs) have been
shown to delay AD onset and reduce the risk of AD development.
In vivo, treatment of APP transgenic mice with NSAIDs
(Ibuprofen: NSAID + choline esterase inhibitor) diminishes
amyloid deposition (Lim et al., 2000, 2001). NSAIDs act directly
on the generation of Abeta (Weggen et al., 2001). Ibuprofen
inhibits GSK-3beta, stabilizes beta-catenin and reverses the
decrease in Wnt signaling due to Abeta (Farías et al., 2005).
NSAID inhibition of beta-catenin requires a high level of
expression of PPAR gamma and its co-receptor RXR-alpha (Lu
et al., 2005). Importantly, NSAIDs also activate PPAR gamma and
inhibit inflammatory processes in the AD brain. This has been the
basis for the use of PPAR gamma agonists in AD (Lehmann et al.,
1997; Heneka et al., 2001a; Landreth and Heneka, 2001; Kielian
and Drew, 2003; Yan et al., 2003; Landreth et al., 2008).
PPAR Gamma in AD
In AD trangenic mice, rosiglitazone attenuates learning and
memory deficits and decreases Abeta-42 in their brain (Pedersen
et al., 2006; Escribano et al., 2010). Memory and cognition are
improved in AD patients treated bymeans of rosiglitazone. PPAR
gamma agonists decrease the Abeta activation of microglia and
prevent hippocampal and cortical neurons from death (Combs
et al., 2000; Kim et al., 2002; Luna-Medina et al., 2005). PPAR
gamma regulates inflammation of microglia due to beta-amyloid
(Combs et al., 2000). PPAR gamma agonists prevent the beta-
amyloid-stimulated expression of the cytokine genes interleukin-
6 and TNF alpha. In the AD mouse (Tg2576) overexpressing
APP, oral treatment for 4 months by pioglitazone decreases Abeta
40 (Yan et al., 2003). Rosiglitazone treatment of Tg2576 mice
induces a reduction of Abeta 42 in the brain (Pedersen et al.,
2006). In aged APP (V7171) transgenic mice, high doses of
pioglitazone diminish microglial and astroglial activation and
Abeta plaques (Heneka et al., 2005).
Other cellular mechanisms can explain the beneficial effects of
PPAR gamma in AD. PPAR gamma modulates APP processing
through a beta-secretase mechanism (Sastre et al., 2003, 2006).
PPAR gamma increases clearance for Abeta (Camacho et al.,
2004). In cultured cells, PPAR gamma overexpression diminishes
Abeta production and increases APP ubiquitination (D’Abramo
et al., 2005). PPAR gamma prevents iNos expression in the SNC
(Heneka et al., 1999, 2000).
Paradoxical Interaction between
Wnt/Beta-Catenin and PPAR Gamma in AD
It has been shown that pioglitazone and rosiglitazone protect rat
hippocampal neurons against Abeta-induced neurodegeneration.
This results in inhibition of GSK-3beta, an increase of beta-
catenin levels and translocation of cytoplasmic beta-catenin to
the nucleus (Inestrosa et al., 2005). Moreover, PPAR gamma
agonists have been shown to activate Wnt/beta-catenin signaling
and induce neuroprotective effects on hippocampal neurons
(Fuentealba et al., 2004). Furthermore, activation of the Wnt
pathway through disheveled and axin induces the stabilization of
the microtubule network, which results in an increase in neurite
length and axonal caliber (Ciani et al., 2004). This outcome
was similar to that observed in neurons treated by troglitazone
and rosiglitazone (Inestrosa et al., 2005). It was concluded that
PPAR gamma activation can prevent neuropathological effects
induced by Abeta, and can induce a positive modulation of
the Wnt pathway in neurons. Moreover, Wnt signaling might
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activate PPAR gamma through AMPK, Sirt1, and PGC1-alpha
(Godoy et al., 2014). Taken together, these data suggest that
activation of PPAR gamma leads to activation of the Wnt/beta-
catenin pathway. This is largely inconsistent with numerous
studies showing that these two systems work in an opposite
manner (Gerhold et al., 2002; Girnun et al., 2002b; Moldes et al.,
2003; Xiao et al., 2003; Sharma et al., 2004; Jansson et al., 2005;
Garcia-Gras et al., 2006; Liu et al., 2006; Takada et al., 2009; Lu
and Carson, 2010). Activation of the Wnt/beta-catenin pathway
represses PPAR gamma and vice versa. Moreover, numerous
studies have shown that Wnt activation improves the AD clinical
status in humans and animal models. Beneficial effects observed
in AD due to PPAR gamma agonists are due to their anti-
inflammatory properties rather than through activation of the
canonical Wnt signaling.
PPAR Alpha in AD
In AD, PPAR alpha and the biological effects of PPAR alpha
agonists have been much less studied than PPAR gamma and
PPAR gamma agonists. Importantly, expression of PPAR alpha
has been shown to be reduced in AD, while that of PPAR gamma
is high (de la Monte and Wands, 2006). PPAR alpha plays a
pivotal role in lipidmetabolism and anti-inflammatory processes.
In many diseases, the expression of PPAR alpha generally varies
inversely with that of PPAR gamma (Lecarpentier et al., 2014).
Thus, in ARVD and cardiac hypertrophy, expression of PPAR
gamma is high and expression of PPAR alpha is low, whereas the
reverse has been observed in type 2 diabetes and hypertension
(Finck et al., 2002; Feige et al., 2006; Djouadi et al., 2009).
Recently, it has been demonstrated that PPAR alpha is able
to stimulate the degradation of APP via the ADAM-10 system
(Corbett et al., 2015). Sequential amyloidogenic proteolysis
of APP by beta-secretase and gamma-secretase generates
pathogenic Abeta between residues 36 and 43. On the other
hand, the non-amyloidogenic juxtamembrane APP cleavage by
alpha secretase, i.e., a disintegrin and metalloproteinase 10
(Adam 10), precludes Abeta generation and results in APP
clearance (Allinson et al., 2003). Mutations in the alpha secretase
ADAM 10 are associated with increased Abeta generation and
AD susceptibility (Suh et al., 2013). Activation of PPAR alpha
upregulates transcription of the alpha-secretase gene. This shifts
the APP processing toward the alpha-secretase pathway. In
neurons, ADAM 10 overexpression diminishes Abeta in an
AD mouse model (Postina et al., 2004). Impairment of the
ADAM 10 synaptic process generates a sporadic AD model
(Epis et al., 2010). In human AD, a decrease in the ADAM
10 function has been reported (Colciaghi et al., 2002, 2004;
Marcello et al., 2013). Knockdown of PPAR alpha (but not PPAR
gamma and beta/delta) decreases the expression of Adam 10 and
overexpression of PPAR alpha restores ADAM 10 expression in
neurons of Ppara −/− mice (Corbett et al., 2015). Moreover,
neurons null for PPAR alpha are deficient in ADAM 10.
Lentiviral delivery of WT PPAR alpha to Ppara −/− neurons
restores of expression of ADAM 10. The WY14643 PPAR alpha
agonist increases ADAM 10 expression in hippocampal neurons.
Activation of PPAR alpha induces the expression of Adam 10
and subsequent alpha-secretase proteolysis of APP. Upregulation
of Adam 10 signaling represents an interesting therapeutic
strategy against overproduction of Abeta. These findings suggest
PPAR alpha could be a therapeutic target for reducing Abeta
burden in AD (Corbett et al., 2015), especially as PPAR alpha
exerts powerful anti-inflammatory effects and Wnt/beta-catenin
activation upregulates PPAR alpha expression (Kozinski and
Dobrzyn, 2013).
CONCLUSION
Alzheimer disease represents the most common form of
senile dementia and is highly neurodegenerative. This review
emphasizes the contrasting behavior of Wnt/beta-catenin
signaling and PPAR gamma in Alzheimer’s disease. It has been
observed that these two systems work in an opposite manner
in numerous pathological situations. In AD, the Wnt/beta-
catenin pathway is downregulated while PPAR gamma is
upregulated. This is also the case in bipolar disease. The
opposite situation has been observed, however, in several
neurodegenerative diseases such as amyotrophic lateral sclerosis,
Parkinson’s disease, Huntington’s disease, multiple sclerosis
and Friedreich’s ataxia. Logically, AD therapy should be based
on the activation of the Wnt/beta-catenin pathway and the
inactivation of PPAR gamma. However, numerous authors have
reported that PPAR gamma agonists produce favorable effects
in Alzheimer’s disease, both in man and transgenic animal
models, but this may well be due to their anti-inflammatory
properties. From a pathophysiological point of view, activation
of the Wnt system/beta-catenin pathway by lithium or riluzole
(both enhancers of the Wnt/beta-catenin signaling) would seem
a logical treatment. However, at the present time Wnt enhancers
have only been used in certain AD animal models. As for PPAR
alpha, interest in its pathophysiological role has recently been
highlighted by enhancing the degradation of the APP through
its action on the Adam 10 pathway. This type of therapy
opens up new possibilities for the treatment of Alzheimer’s
disease.
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